Archives of Neurology · 1974 · 56 citations · 17 references
Life SciencesBiochemistryNeurologyGlycobiologyNeurogeneticsPediatric NeurologyLysosomal Storage DisordersNervous TissueNeurodegenerative DiseasesNeurodegenerative DisordersPediatric Neurologic DisordersCeramide BiosynthesisCeramide MetabolismEnzyme ActivityEnzyme Activity RegulationGanglioside BiosynthesisNomenclature
A 12-year-old girl with G<sub>M1</sub>gangliosidosis had been well until 5 years of age when she first developed spasticity and slow progressive intellectual deterioration. When assayed with artificial substrates (<i>p</i>-nitrophenyl-β-galactoside and 4-methylumbelliferyl-β-galactoside), βgalactosidase activity was virtually absent in leukocytes, urinary protein, and cultured fibroblasts. Enzyme activity was also decreased when the natural substrates G<sub>M1</sub>ganglioside (5% of control cells) and ceramide lactoside (24% of control cells) were used. Cerebroside βgalactosidase activity was in the high normal range. We propose a new nomenclature for the G<sub>M1</sub>gangliosidoses in which this patient would be classified as having the juvenile O variant.
17
ENZYME ALTERATIONS AND LIPID STORAGE IN THREE VARIANTS OF TAY‐SACHS DISEASE
Konrad Sandhoff, K. Harzer, Werner Wässle et al. · Journal of Neurochemistry · 1971 · 293 citations
Familial Neurovisceral Lipidosis
Benjamin H. Landing · American journal of diseases of children · 1964 · 185 citations
Medicine, Pathobiology, Pathology +15